Related Experiment Video
Updated: Apr 17, 2026
An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma
Published on: November 15, 2024
The 9L(LUC)/Wistar rat glioma model is not suitable for immunotherapy
Liping Yang1, Jingxiang Zhao2, Guihong Zhou3
1Department of Medicine, the 263 Hospital, Beijing 101149, China ; Department of Neurology, South West Hospital, the Third Military Medical University of Chinese PLA, Chongqing 400038, China.
Abstract:
The availability of a well-characterized animal brain tumor model will play an important role in identifying treatments for human brain tumors. Wistar rats bearing 9L glioma cells can develop solid, well-circumcised tumors, and may be a useful animal model for the evaluation of various therapeutic approaches for gliosarcomas. In this study, the 9L/Wistar rat glioma model was produced by intracerebral implantation of 9L(LUC) glioma cells syngenic to Fischer 344 (F344) rats. Bioluminescence imaging showed that tumors progressively grew from day 7 to day 21 in 9L(LUC)/F344 rats, and tumor regression was found in some 9L(LUC)/Wistar rats. Hematoxylin-eosin staining verified that intracranial tumors were gliomas. Immunohistochemistry results demonstrated that no CD4- and CD8-positive cells were found in the syngeneic 9L(LUC)/F344 model. However, many infiltrating CD4- and CD8-positive cells were observed within the tumors of the 9L(LUC)/Wistar model. Our data suggests that compared with 9L/F344 rats, 9L glioma Wistar rats may not be suitable for evaluating brain glioma immunotherapies, even though the model induced an immune response and exhibited tumor regression.
